DALLAS, June 25, 2015 /PRNewswire/ --
The Global Cancer Vaccines Market 2015-2019 report says use of vaccines in combination with other therapies is propelling the growth of cancer vaccines market across the world in addition to frequent occurrence of different types of cancer and the introduction of various cancer vaccines.
Complete report on cancer vaccines market spread across 64 pages, talking about 3 major companies and supported with 24 exhibits is now available at http://www.reportsnreports.com/reports/402767-global-cancer-vaccines-market-2015-2019.html .
Factors such as increasing number of people with cancer, rising public awareness of vaccines, presence of promising late-stage pipeline candidates, and vendors' patient-assistance programs also augment growth in the cancer vaccines market. Dendritic cells are cells taken from a patient's immune system and treated with chemicals before being injected back into the patient. These cells produce an enhanced immune response against the malignant cells in the body and stimulate the other cells in the immune system to fight the cancerous cells.
Physicians prefer a combination of cancer vaccines with pharmacotherapeutics to treat cancer. This not only increases the efficacy of the treatment but also helps improve the overall survival rate of patients. On the other hand, from corporate perspective, strategic alliances not only help a vendor increase its market penetration but they also enhance the vendor's product portfolio. For instance, GAVI Alliance aims to immunize about 2-million females in developing regions in 2015 using the HPV vaccines Cervarix and Gardasil, which are supplied at a low cost by GlaxoSmithKline and Merck. In 2015, Bristol-Myers Squibb collaborated with Bavarian Nordic to develop Prostvac, a therapeutic vaccine for the treatment of prostate cancer. Together, in 2015, Advaxis and Incyte evaluated ADXS-HPV using Incyte's investigational oral indoleamine 2,3-dioxygenase 1 inhibitor, epacadostat. In 2014, Boehringer Ingelheim and CureVac entered into an agreement to develop and commercialize a lung cancer vaccine — CV9202 — using CureVac's RNA technology, RNActive.
According to this new cancer vaccines market report, cancer is a leading cause of deaths worldwide. The World Health Organization says 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers. Further, the report states that cold chain, or temperature-controlled supply chain, management is a major challenge for this market.
The following companies are the key players in the global cancer vaccines market and discussed at length in this research: Dendreon, GlaxoSmithKline and Merck. Other Prominent Vendors simply mentioned in this report include Aduro BioTech, Advantagene, Advaxis, Agenus, AlphaVax, Altor BioScience, Amgen, Antigen Express, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Bristol-Myers Squibb, Celldex Therapeutics, Cel-Sci, CureVac, Cytos, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Immutep, Inovio Pharmaceuticals, Isa Pharmaceuticals, Juvaris Biotherapeutics, MedImmune, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Progenics, Provectus Biopharmaceuticals, Sanofi, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech and Vical. Order a copy of Global Cancer Vaccines Market 2015-2019 research report at http://www.reportsnreports.com/Purchase.aspx?name=402767 .
Key drivers of the cancer vaccines market discussed in this 2015 research report include increase in prevalence of cancers, strong late-stage pipeline vaccine candidates, and increase in awareness and patient-assistance programs. Trends like strategic alliances, vaccines used in combination with other therapies and growth in emerging markets are also covered. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:
- Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil.
- EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE.
- APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is untapped by the leading vendors.
Another related research titled Cancer Vaccine Partnering Terms and Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the world's leading healthcare companies including data and information on trends in cancer vaccine partnering deals, disclosed headlines, upfronts, milestones and royalties by stage of development, cancer vaccine partnering contract documents and top cancer vaccine deals by value. The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This report contains over 160 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This research lists available deals by: Company A-Z, Headline value, Stage of development at signing, Deal component type and Specific oncology therapy target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Order a copy of Cancer Vaccine Partnering Terms and Agreements report at http://www.reportsnreports.com/Purchase.aspx?name=149831 .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: http://www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
G+ / Google Plus:https://plus.google.com/111656568937629536321/posts
Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
SOURCE ReportsnReports
Share this article